This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Despite extensive research into genetic factors affecting the therapeutic response to antiepileptic drugs (AEDs), no biomarkers predictive of AED efficacy have been identified to date,1 and the only influence of genetic testing in choosing the most effective treatment stems from its use in diagnosing rare monogenic epilepsies requiring specific therapies.2,3 The search for genetic predictors of adverse drug reactions (ADRs), by contrast, has been rewarding.
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the editorial.
Genetic variation in CFH predicts phenytoin-induced maculopapular exanthema in European-descent patients 165
- Copyright © 2017 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Alert Me
Recommended articles
HLA-A*24:02 as a common risk factor for antiepileptic drug–induced cutaneous adverse reactions
Genetic variation in CFH predicts phenytoin-induced maculopapular exanthema in European-descent patients
Real-world cost-effectiveness of pharmacogenetic screening for epilepsy treatment
Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians